(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 August 2008 (21.08.2008)

PCT

(10) International Publication Number
WO 2008/099178 A3

(51) International Patent Classification:
C07K 16/42 (2006.01) *C07K 16/26* (2006.01)
C07K 19/00 (2006.01) *A61P 11/00* (2006.01)
C07K 14/705 (2006.01) *C12N 15/13* (2006.01)
A61P 37/08 (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/GB2008/000510

(22) International Filing Date:
15 February 2008 (15.02.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/901,304 15 February 2007 (15.02.2007) US

(71) Applicants *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE). **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **COCHRANE, Duncan** [GB/GB]; Medimmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **COHEN, Suzanne** [GB/GB]; Medimmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **DOBSON, Claire, Louise** [GB/GB]; Medimmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **ERIKSSON, Per-Olof, Fredrik** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **MONK, Phillip, David** [GB/GB]; Synairgen PCL/Synairgen Research, Mailpoint 810, Level F, Southampton General Hospital, Tremona Road, Southampton Hampshire SO16 6YD (GB). **VON-WACHENFELDT, Karin** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
16 October 2008

(54) Title: BINDING MEMBERS FOR IGE MOLECULES

(57) Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.

WO 2008/099178 A3